Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 3Breast Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

zimberelimab 1PM 01183 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × PM 01183 × Gynecologic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡